Healthcare cases account for approximately 15% of MBB consulting interviews and are among the most complex due to multiple stakeholders, heavy regulation, and intricate payment systems. Unlike consumer industries where pricing follows market dynamics, healthcare operates under a web of government rules, insurance negotiations, and clinical considerations. This guide provides the complete framework to navigate healthcare cases with confidence.
Products and Services Landscape
Healthcare is not one industry — it’s an interconnected ecosystem of sub-sectors with fundamentally different business models. Identifying which sub-sector your case addresses in the first 60 seconds is critical.
| Sub-Sector | Key Products/Services | Typical Margins | Key Success Factors |
|---|---|---|---|
| Hospitals & Health Systems | Inpatient care, outpatient services, emergency, surgery | Operating margin 2-8% | Payer mix, occupancy rates, labor efficiency |
| Pharmaceuticals | Branded drugs, generics, biologics, vaccines | Gross margin 70-90%, Net 15-25% | R&D pipeline, patent life, pricing power |
| Medical Devices | Implants, diagnostics, surgical equipment, monitoring | Gross margin 60-75% | Clinical evidence, physician relationships |
| Health Insurance/Payers | Insurance products, pharmacy benefits, care management | Net margin 3-6% | Medical loss ratio, member acquisition |
| Pharmacy/PBM | Drug dispensing, specialty pharmacy, mail order | Gross margin 20-25% | Scale, rebate negotiations, generic substitution |
| Healthcare IT | EHR, analytics, telehealth, revenue cycle | SaaS margins 70-80% | Interoperability, switching costs |
| Diagnostics/Labs | Clinical testing, imaging, pathology | Gross margin 40-60% | Volume, automation, turnaround time |
Based on our analysis of 800+ healthcare cases, the most common sub-sectors tested are hospitals (35%), pharmaceuticals (30%), and medical devices (20%).
Revenue Tree: Understanding Healthcare Economics
Healthcare revenue models differ fundamentally from typical B2C or B2B industries. The person receiving the service (patient) is often not the one paying (insurer/government).
Healthcare Revenue Equation
Healthcare Revenue = Volume × Reimbursement Rate × Collection Rate
Where:
- Volume = Number of services/procedures/prescriptions
- Reimbursement Rate = Negotiated or regulated payment per service
- Collection Rate = Actual collections as % of billed charges
flowchart TD
A[Total Revenue] --> B[Patient Services]
A --> C[Non-Patient Revenue]
B --> D[Inpatient]
B --> E[Outpatient]
B --> F[Emergency]
D --> D1[Admissions]
D --> D2[Length of Stay]
D --> D3[Case Mix Index]
E --> E1[Visits]
E --> E2[Procedures]
E --> E3[Ancillary Services]
C --> G[Research Grants]
C --> H[Retail/Pharmacy]
C --> I[Parking/Other]
style A fill:#1e3a5f,color:#fff
style B fill:#2563eb,color:#fff
style C fill:#2563eb,color:#fff
Revenue by Payer Type
Understanding payer mix is essential — it directly impacts reimbursement rates and collection rates.
| Payer Type | % of US Healthcare Spend | Typical Reimbursement vs. Charges | Collection Rate | Key Dynamics |
|---|---|---|---|---|
| Medicare | 23% | 40-60% of charges | 95%+ | Government-set rates, DRG-based for inpatient |
| Medicaid | 17% | 30-50% of charges | 90-95% | State-administered, lowest rates |
| Commercial Insurance | 34% | 80-120% of charges | 85-95% | Negotiated rates, highest reimbursement |
| Self-Pay/Uninsured | 10% | 100% of charges (billed) | 10-30% | High bad debt risk |
| Other (VA, Workers Comp) | 16% | Varies | Varies | Government programs |
A hospital with 60% Medicare/Medicaid payer mix faces fundamentally different economics than one with 60% commercial — this is often a case-defining insight.
Pharmaceutical Revenue Model
Drug company revenue follows a different logic:
Pharma Revenue = Patients × Treatment Duration × Price × Market Share
| Revenue Driver | Key Metrics | Benchmarks | Diagnostic Questions |
|---|---|---|---|
| Patient Pool | Disease prevalence, diagnosis rate | Varies by condition | Is this a common or rare disease? |
| Treatment Duration | Chronic vs. acute, cure vs. maintenance | Oncology: months; Chronic: years | How long do patients stay on therapy? |
| Price | WAC, ASP, net price after rebates | Specialty: $50K-500K/year; Generic: $10-100/year | Is pricing protected by patents? |
| Market Share | Competitive position, formulary status | Leader: 30-50%; Follower: 10-20% | What’s the competitive landscape? |
Cost Structure: Where Healthcare Dollars Go
Hospital Cost Structure
pie title Hospital Cost Structure (% of Operating Expenses)
"Labor" : 55
"Supplies & Drugs" : 18
"Purchased Services" : 10
"Facilities & Equipment" : 8
"Other" : 9
| Cost Category | % of Revenue | Sub-Components | Optimization Levers |
|---|---|---|---|
| Labor | 50-60% | Nursing (largest), physicians, technicians, admin | Staffing ratios, productivity, locum reduction |
| Supplies & Drugs | 15-20% | Surgical supplies, pharmaceuticals, implants | GPO negotiation, standardization, formulary |
| Purchased Services | 8-12% | Contract labor, IT, consulting, outsourced services | Insourcing evaluation, vendor consolidation |
| Facilities & Equipment | 6-10% | Depreciation, maintenance, utilities, capital leases | Capacity utilization, energy efficiency |
| Bad Debt & Charity | 3-8% | Uncompensated care, write-offs | Financial counseling, eligibility screening |
Pharmaceutical Cost Structure
| Cost Category | % of Revenue | Key Drivers | Industry Notes |
|---|---|---|---|
| R&D | 15-25% | Drug discovery, clinical trials, regulatory | $2.6B average cost to bring a drug to market |
| Manufacturing (COGS) | 20-30% | API, formulation, packaging, quality | Biologics have higher manufacturing costs |
| Sales & Marketing | 20-30% | Sales reps, DTC advertising, physician outreach | US allows DTC; most countries do not |
| SG&A | 10-15% | Corporate overhead, legal, compliance | Patent litigation is a major expense |
| Rebates & Discounts | 20-40% of gross | PBM rebates, Medicaid best price, 340B | The gap between gross and net price |
Key insight: Pharmaceutical “list price” and actual realized price can differ by 30-50% due to rebates and discounts. Always clarify which price is being discussed.
Competitive Landscape
Healthcare competition operates differently across sub-sectors due to regulation, local market dynamics, and the role of intermediaries.
Porter’s Five Forces for Healthcare
| Force | Hospitals | Pharma | Medical Devices |
|---|---|---|---|
| Rivalry | Medium (local markets, consolidation) | High (patent cliffs, me-too drugs) | Medium-High (clinical differentiation) |
| New Entrants | Low (capital, CON laws, accreditation) | Medium (generics easy, branded hard) | Medium (regulatory barriers) |
| Supplier Power | Medium (GPOs, labor shortages) | Low (commodity APIs) | Low-Medium (raw materials) |
| Buyer Power | High (payers, employers) | High (PBMs, formularies) | Medium (hospital value analysis) |
| Substitutes | Medium (outpatient, home health) | High (generics, biosimilars, alternative therapies) | Medium (newer technologies) |
Healthcare Competitive Response Framework
flowchart LR
A[Competitive Threat] --> B{Response Type}
B --> C[Clinical Differentiation]
B --> D[Cost Leadership]
B --> E[Access Strategy]
B --> F[Vertical Integration]
C --> C1[Quality outcomes, specialty programs]
D --> D1[Scale, efficiency, standardization]
E --> E1[Payer contracts, network inclusion]
F --> F1[Own payer, pharmacy, ambulatory]
style A fill:#1e3a5f,color:#fff
style B fill:#2563eb,color:#fff
Customer Analysis
Healthcare “customers” are complex — multiple stakeholders influence purchasing decisions, and the end user (patient) often has limited choice.
Healthcare Stakeholder Map
| Stakeholder | Role | Key Concerns | Influence on Decision |
|---|---|---|---|
| Patient | End user of care | Quality, access, out-of-pocket cost | Limited choice (especially for hospitals) |
| Physician | Prescriber/decision-maker | Clinical efficacy, ease of use, liability | High (especially for devices, drugs) |
| Payer (Insurance) | Financing and gatekeeping | Cost, outcomes, network management | Very high (formulary, prior auth, network) |
| Hospital/Health System | Care delivery platform | Margin, quality scores, patient volume | High for supplies, services |
| PBM | Pharmacy benefit intermediary | Rebates, formulary control, mail order | Very high for drug access |
| Employer | Plan sponsor | Total cost of care, employee satisfaction | Increasing (direct contracting) |
| Regulator | Approval and oversight | Safety, efficacy, compliance | Gate-keeping (FDA, CMS) |
Patient Segmentation
| Segment | Characteristics | Healthcare Utilization | Strategic Implications |
|---|---|---|---|
| Healthy/Low Utilizers | <2 visits/year, minimal Rx | Low cost, high profit for payers | Wellness, prevention focus |
| Chronic Disease | Diabetes, heart disease, asthma | Moderate-high, predictable | Care management, medication adherence |
| High-Cost/Complex | Multiple conditions, frequent hospitalization | Very high, 5% of patients = 50% of costs | Intensive care coordination |
| Acute Episodic | Surgery, injury, pregnancy | Concentrated, plannable | Bundled payments, centers of excellence |
Distribution Channels
Healthcare distribution is highly regulated and varies significantly by product type.
Drug Distribution Channel
flowchart LR
A[Manufacturer] --> B[Wholesaler]
B --> C1[Retail Pharmacy]
B --> C2[Hospital Pharmacy]
B --> C3[Specialty Pharmacy]
B --> C4[Mail Order]
C1 --> D[Patient]
C2 --> D
C3 --> D
C4 --> D
A --> E[PBM]
E --> C1
E --> C3
E --> C4
style A fill:#1e3a5f,color:#fff
style E fill:#dc2626,color:#fff
style D fill:#1e3a5f,color:#fff
Channel Economics
| Channel | Margin to Intermediary | Volume | Control/Access | Best For |
|---|---|---|---|---|
| Hospital Direct | 5-15% | High | High formulary control | High-cost, administered drugs |
| Retail Pharmacy | 15-25% | Very High | Limited control | Generics, common Rx |
| Specialty Pharmacy | 20-30% | Low | High patient support | Biologics, complex therapies |
| Mail Order | 10-20% | High | PBM controlled | Chronic, maintenance drugs |
| Physician Office (Buy & Bill) | 20-30% markup | Medium | Physician choice | Injectable drugs, vaccines |
Supply Chain
Healthcare supply chains are complex, highly regulated, and increasingly global.
Hospital Supply Chain
| Category | % of Supply Spend | Key Players | Strategic Considerations |
|---|---|---|---|
| Medical/Surgical Supplies | 40-50% | Cardinal, Medline, Owens & Minor | GPO contracts, standardization |
| Pharmaceuticals | 30-40% | McKesson, AmerisourceBergen, Cardinal | 340B eligibility, specialty drugs |
| Implants & High-Cost Devices | 15-20% | Medtronic, J&J, Stryker | Physician preference items |
| Capital Equipment | 5-10% | GE, Siemens, Philips | Long replacement cycles |
Pharmaceutical Supply Chain Metrics
| Metric | Definition | Benchmark | Significance |
|---|---|---|---|
| Days of Inventory | Average inventory / Daily COGS | 60-90 days | Working capital efficiency |
| OTIF (On-Time In-Full) | % orders delivered complete and on time | 98%+ | Service level |
| Cold Chain Compliance | % shipments maintaining temperature | 99.9%+ | Critical for biologics |
| Recall Response Time | Time to remove recalled product | <24 hours | Patient safety |
| Supply Continuity Rate | % time without stockouts | 99.5%+ | Drug shortage prevention |
Key Industry Trends
These trends frequently appear in healthcare cases and are important context for any recommendation.
| Trend | Impact | Case Relevance | Key Data |
|---|---|---|---|
| Value-Based Care Shift | Moving from fee-for-service to outcomes-based payment | Provider strategy, payer cases | 40% of payments now have value component |
| Consolidation | Horizontal and vertical M&A across healthcare | M&A cases, market entry | Top 10 health systems now control 25% of beds |
| Drug Pricing Pressure | Government and payer pushback on high prices | Pharma pricing, market access | IRA caps Medicare drug costs; state price controls expanding |
| Workforce Crisis | Nursing and clinician shortages | Operations, labor strategy | 200,000+ nurse shortage projected by 2030 |
| Digital Health & AI | Telehealth, AI diagnostics, remote monitoring | Technology strategy, new products | Telehealth visits up 38x since 2019 (though normalizing) |
| Specialty Drug Growth | Shift from primary care to specialty therapies | Pharma strategy, distribution | Specialty drugs: 2% of Rx volume but 50%+ of spend |
Important Terminology
Master these terms before your healthcare case interview:
Reimbursement & Payment Terms
| Term | Definition | Usage Context |
|---|---|---|
| DRG (Diagnosis Related Group) | Payment classification grouping similar cases | Hospital inpatient reimbursement |
| CPT Code | Procedure code used for billing | Physician/outpatient billing |
| RVU (Relative Value Unit) | Measure of physician work/resource use | Physician compensation |
| MLR (Medical Loss Ratio) | % of premiums spent on medical care | Payer profitability (must be >80%) |
| PMPM (Per Member Per Month) | Monthly cost per enrolled member | Payer/capitation discussions |
| ASP (Average Sales Price) | Average price Medicare uses for Part B drugs | Drug reimbursement |
| AWP (Average Wholesale Price) | Benchmark price for drugs | Often called “Ain’t What’s Paid” |
Clinical & Operational Terms
| Term | Definition | Usage Context |
|---|---|---|
| Case Mix Index (CMI) | Average complexity of patients treated | Hospital acuity/reimbursement |
| Length of Stay (LOS) | Average days per hospital admission | Efficiency metric |
| HCAHPS | Patient satisfaction survey (required) | Quality scores |
| Readmission Rate | % patients returning within 30 days | Quality penalty trigger |
| FTE | Full-Time Equivalent (for staffing) | Labor productivity |
| Prior Authorization | Payer approval required before treatment | Access/coverage decisions |
Pharmaceutical Terms
| Term | Definition | Usage Context |
|---|---|---|
| NDA/BLA | New Drug Application / Biologics License Application | FDA approval process |
| ANDA | Abbreviated NDA (for generics) | Generic drug entry |
| WAC (Wholesale Acquisition Cost) | Manufacturer list price | Baseline for discounts |
| Rebate | Discount paid after sale to PBM/payer | Net price calculation |
| Formulary | List of drugs covered by a plan | Market access |
| Step Therapy | Requirement to try cheaper drugs first | Access restriction |
| Patent Cliff | Revenue drop when patents expire | Lifecycle management |
Important Calculations
These calculations frequently appear in healthcare cases.
Hospital Profitability
Operating Margin = (Operating Revenue - Operating Expenses) / Operating Revenue
- Average hospital: 2-4%
- Top quartile: 8-12%
Net Patient Revenue per Adjusted Discharge = Net Patient Revenue / (Discharges + Outpatient Equivalents)
- Varies by region: $12,000-$20,000
Labor Cost per Adjusted Patient Day = Total Labor Cost / Adjusted Patient Days
- Benchmark: $1,500-$2,500
Occupancy Rate = Patient Days / (Beds × 365)
- Target: 70-85% (too high = capacity strain)
Pharmaceutical Economics
Gross-to-Net Discount = (WAC Price - Net Realized Price) / WAC Price × 100
- Ranges from 20% (protected specialty) to 80%+ (competitive generics)
Cost per Patient per Year = Annual Dose × Doses per Year × Net Price per Dose
- Used for budget impact analysis
QALY (Quality-Adjusted Life Year) = Years of life × Quality weight (0-1)
- $50,000-$150,000 per QALY is typical threshold for cost-effectiveness
Patent Remaining Life Value = NPV of remaining patent-protected revenues
- Critical for M&A valuation
Payer Economics
Medical Loss Ratio = (Medical Costs + Quality Improvement) / Premium Revenue
- ACA requires: 80% individual/small group, 85% large group
Combined Ratio = Medical Loss Ratio + Administrative Cost Ratio
- Target: <100% (otherwise losing money)
PMPM (Per Member Per Month) = Total Cost / (Members × Months)
- Allows comparison across different plan sizes
Important Considerations
These are the factors that separate strong candidates from average ones in healthcare cases.
Common Pitfalls
Ignoring the Payer Mix: A 5% Medicare rate cut has different impact depending on payer mix. Always ask about payer composition.
Forgetting Regulation: Healthcare is heavily regulated. Market entry, pricing changes, and new products all face regulatory hurdles.
Confusing Price with Revenue: Drug “price increases” may not translate to revenue growth if rebates increase proportionally.
Overlooking Stakeholder Complexity: The buyer isn’t the user isn’t the payer. Map all stakeholders before recommending.
Assuming National Scale: Healthcare is often local. A strategy that works in one market may not transfer to another.
Questions to Always Ask
- What type of healthcare entity is this (hospital, pharma, device, payer)?
- What is the payer mix or customer composition?
- Is this a regulated product/service? What approvals are needed?
- Who makes the purchasing decision (physician, hospital, payer, patient)?
- What is the competitive landscape? Are there patent or exclusivity protections?
- What are the key quality/outcome metrics being tracked?
Red Flags in Healthcare Cases
| Signal | What It Suggests | Follow-Up Analysis |
|---|---|---|
| Operating margin declining despite volume growth | Payer mix shift or cost inflation | Analyze margin by payer, labor cost trends |
| High gross-to-net spread increasing | Competitive pressure, rebate demands | Evaluate pricing sustainability, formulary status |
| Readmission rates above benchmark | Quality issues, care coordination gaps | Assess discharge process, post-acute partnerships |
| Physician alignment declining | Compensation, administrative burden | Survey physicians, compare to market |
| Drug pipeline concentrated | Risk if trials fail | Assess portfolio diversification, BD opportunities |
Key Takeaways
- Healthcare cases require immediate sub-sector identification — hospitals, pharma, devices, and payers have fundamentally different economics
- Revenue follows the equation: Volume × Reimbursement × Collection; always ask about payer mix
- Labor is 50-60% of hospital costs; R&D is 15-25% of pharma revenue — know the cost structures cold
- Multiple stakeholders influence healthcare decisions: map the patient, physician, payer, and regulator roles
- Regulation shapes everything: FDA approvals, CMS reimbursement rules, and state-level requirements matter
- Key metrics by sub-sector: operating margin for hospitals, gross-to-net for pharma, MLR for payers
- Trends to know: value-based care shift, consolidation, workforce shortages, specialty drug growth
Ready to practice? Browse healthcare industry cases in our case library, or test your framework in a timed AI Mock Interview to build speed and confidence.